FR10C0056I1 - - Google Patents

Info

Publication number
FR10C0056I1
FR10C0056I1 FR10C0056C FR10C0056I1 FR 10C0056 I1 FR10C0056 I1 FR 10C0056I1 FR 10C0056 C FR10C0056 C FR 10C0056C FR 10C0056 I1 FR10C0056 I1 FR 10C0056I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0056(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR10C0056I1 publication Critical patent/FR10C0056I1/fr
Application granted granted Critical
Publication of FR10C0056I2 publication Critical patent/FR10C0056I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR10C0056C 1994-03-02 2010-12-23 Active FR10C0056I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94200521 1994-03-02
PCT/EP1995/000765 WO1995023600A1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition
EP95912188A EP0746317B1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition

Publications (2)

Publication Number Publication Date
FR10C0056I1 true FR10C0056I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-01-28
FR10C0056I2 FR10C0056I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-11-25

Family

ID=8216678

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0056C Active FR10C0056I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-03-02 2010-12-23

Country Status (22)

Country Link
US (1) US5763476A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0746317B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4099224B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100330942B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1079670C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE167057T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU692530B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR9506924A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2182981C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ284633B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69502939T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0746317T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2118584T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI117923B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR10C0056I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU225051B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91751I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO308772B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ282394A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL180465B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2139051C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995023600A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
ATE516799T1 (de) * 2002-02-13 2011-08-15 Michael K Weibel Arzneimitteldosenform und -herstellungsverfahren
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
CA2539494C (en) * 2003-09-22 2011-12-06 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
AU2005293552B2 (en) * 2004-10-15 2011-04-14 Msd Oss B.V. Treatment of bipolar disorders and associated symptoms
TWI364423B (en) * 2005-04-07 2012-05-21 Msd Oss Bv Crystal form of asenapine maleate
DE602006010132D1 (de) 2005-04-07 2009-12-17 Organon Nv Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
MX2012000061A (es) 2009-06-24 2012-06-01 Msd Oss Bv Formulaciones inyectables que contienen asenapina, y metodo de tratamiento usando las mismas.
TW201118102A (en) 2009-07-29 2011-06-01 Organon Nv Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
CA2802990A1 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
JP5815702B2 (ja) 2010-07-29 2015-11-17 ラボラトリオス レスヴィ，エス．エル． アセナピンの新規な製造方法
WO2012038975A2 (en) * 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
EA027840B1 (ru) 2010-11-15 2017-09-29 Эйджинбайо, Инк. Производные пиридазина, композиции и способы лечения когнитивного нарушения
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
WO2012156677A1 (en) 2011-05-18 2012-11-22 Laboratorios Lesvi S.L. A stable micronised monoclinic form of asenapine maleate and its synthesis
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
CN102657635B (zh) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
RU2015128794A (ru) 2012-12-20 2017-01-25 КАШИВ ФАРМА, ЭлЭлСи Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
CN103893139B (zh) * 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
CN103120688A (zh) * 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
WO2014116770A1 (en) * 2013-01-23 2014-07-31 Arx, Llc Production of unit dose constructs
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
IN2013MU02206A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
US20170007537A1 (en) * 2014-02-18 2017-01-12 Hetero Research Foundation Pharmaceutical compositions of asenapine
CN106535898A (zh) 2014-04-04 2017-03-22 细胞内治疗公司 有机化合物
TR201509009A1 (en) * 2014-12-11 2017-02-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi THIN FILM STRIP OF ASENAPINE
EP3307245A1 (en) 2015-06-11 2018-04-18 Alrise Biosystems GmbH Process for the preparation of drug loaded microparticles
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
PL3407888T3 (pl) 2016-01-26 2021-08-30 Intra-Cellular Therapies, Inc. Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania
KR102684468B1 (ko) 2016-03-25 2024-07-11 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7236389B2 (ja) 2016-12-20 2023-03-09 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
MX2020009668A (es) 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Métodos novedosos.
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110958876B (zh) 2018-06-20 2020-12-18 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
FR2480283A1 (fr) * 1980-04-10 1981-10-16 Science Union & Cie Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
JPS5967218A (ja) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA2027243A1 (en) * 1989-10-17 1991-04-18 Everett H. Ellinwood, Jr. Intraoral formulated trifluorobenzodiazepines and the use thereof
US5496559A (en) * 1991-04-08 1996-03-05 Sumitomo Pharmaceuticals Company, Limited Porous solid formulations containing proteinaceous physiologically active substances
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation

Also Published As

Publication number Publication date
CA2182981C (en) 2006-10-17
CZ254196A3 (en) 1997-10-15
ATE167057T1 (de) 1998-06-15
JP4616810B2 (ja) 2011-01-19
JPH09509674A (ja) 1997-09-30
HK1008417A1 (en) 1999-05-07
RU2139051C1 (ru) 1999-10-10
NO963639D0 (no) 1996-08-30
DE122010000050I2 (de) 2011-07-21
FI963398A0 (fi) 1996-08-30
DE122010000050I1 (de) 2011-05-05
FI963398L (fi) 1996-08-30
KR100330942B1 (ko) 2002-11-16
NO2010024I1 (no) 2011-01-03
CA2182981A1 (en) 1995-09-08
NO963639L (no) 1996-10-30
EP0746317A1 (en) 1996-12-11
BR9506924A (pt) 1997-09-30
FI117923B (fi) 2007-04-30
HUT76319A (en) 1997-08-28
NO308772B1 (no) 2000-10-30
HU225051B1 (en) 2006-05-29
JP4099224B2 (ja) 2008-06-11
US5763476A (en) 1998-06-09
AU1947895A (en) 1995-09-18
ES2118584T3 (es) 1998-09-16
DK0746317T3 (da) 1999-03-22
WO1995023600A1 (en) 1995-09-08
HU9602383D0 (en) 1996-10-28
BR1100625A (pt) 1999-12-28
PL180465B1 (pl) 2001-02-28
NO2010024I2 (no) 2012-04-10
DE69502939D1 (de) 1998-07-16
FR10C0056I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-11-25
CZ284633B6 (cs) 1999-01-13
EP0746317B1 (en) 1998-06-10
JP2006342178A (ja) 2006-12-21
LU91751I2 (fr) 2011-01-04
PL316080A1 (en) 1996-12-23
CN1079670C (zh) 2002-02-27
DE69502939T2 (de) 1998-10-22
MX9603713A (es) 1997-12-31
CN1143320A (zh) 1997-02-19
AU692530B2 (en) 1998-06-11
NZ282394A (en) 1997-12-19

Similar Documents

Publication Publication Date Title
FR10C0056I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW281727B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW264422B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR19980700562A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0677466T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0666525A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW281718B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0669187A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2727790B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW288034B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW282504B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN192542B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0666470A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0667387A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE69535748D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2721512B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0667627A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2728027B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW279973B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0662420A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940191S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU22453A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BRPI9401073A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK40195A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI940181S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)